Whole exome sequencing of germline DNA of individuals presenting extreme phenotypes of high and low risk to develop tobacco-induced lung adenocarcinoma (LUAD) according to KRAS status.
José Luis Perez‐Gracia(Clinica Universidad de Navarra), Ana Patiño‐García(Navarre Institute of Health Research), Maria Pilar Andueza(Clinica Universidad de Navarra), Guillermo Pita(Spanish National Cancer Research Centre), Elisabet Guruceaga(Universidad de Navarra), Miguel F. Sanmamed(Clinica Universidad de Navarra), María J. Pajares(Universidad Pública de Navarra (UPNA)), Ignacio Melero(University of Oxford), Anna González‐Neira(Spanish National Cancer Research Centre), Alfonso Gúrpide(Clinica Universidad de Navarra), Carlos E. de Andrea(Navarre Institute of Health Research), Rodrigo Sánchez-Bayona(Research Institute Hospital 12 de Octubre), Javier J. Zulueta(Mount Sinai Hospital), María I. Mora(Clinica Universidad de Navarra), María E. Rodríguez-Ruiz(Navarre Institute of Health Research), Víctor Segura(Universidad de Navarra), Ruben Pio Oses(Centro de Investigación Médica Aplicada), Juan P. Fusco, Luis M. Montuenga(Clinica Universidad de Navarra)
Cited by 1
Related Papers
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|2.2k
Comorbidities and Risk of Mortality in Patients with Chronic Obstructive Pulmonary Disease
|American Journal of Respiratory and Critical Care Medicine|2012|1.3k
Cytokines in clinical cancer immunotherapy
|British Journal of Cancer|2018|1.2k
Large-scale genotyping identifies 41 new loci associated with breast cancer risk
|Nature Genetics|2013|1.1k